Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss

Clinical Immunology

Volumn 133, Issue 2, 2009, Pages 265-275

  Graham, Lucia S ^a   Parhami, Farhad ^a   Tintut, Yin ^a   Kitchen, Christina M R ^b   Demer, Linda L ^a   Effros, Rita B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone; Human; Lipids; Mouse; Osteoporosis; RANKL; T lymphocytes

Indexed keywords

8 ISOPROSTAGLANDIN E2; LIPID; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OXIDIZED LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL INTERACTION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID OXIDATION; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; BONE DENSITY; BONE RESORPTION; CELL NUCLEUS; DIETARY FATS; DINOPROSTONE; GENE EXPRESSION; HUMANS; ISOPROSTANES; LIPIDS; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOPROTEGERIN; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINES; RANK LIGAND; SCAVENGER RECEPTORS, CLASS E; T-LYMPHOCYTES; TRANSCRIPTION FACTOR RELA;

EID: 70349780392     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.07.011     Document Type: Article

References (78)

1. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., and Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 22 (2007) 465-475
2. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 (2002) 1929-1936
3. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., and Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24 (2006) 33-63
4. Arron J.R., and Choi Y. Bone versus immune system. Nature 408 (2000) 535-536
5. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y., and Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 (1997) 25190-25194
6. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
7. Wong B.R., Josien R., and Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc. Biol. 65 (1999) 715-724
8. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., and Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3597-3602
9. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., and Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
10. Vanderborght A., Linsen L., Thewissen M., Geusens P., Raus J., and Stinissen P. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J. Rheumatol. 31 (2004) 1483-1490
11. Liu D., Xu J., Figliomeni L., Huang L., Pavlos N., Rogers M., Tan A., Price P., and Zheng M. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int. J. Mol. Med. 11 (2003) 17-21
12. Baker P.J., Howe L., Garneau J., and Roopenian D.C. T cell knockout mice have diminished alveolar bone loss after oral infection with Porphyromonas gingivalis. FEMS Immunol. Med. Microbiol. 34 (2002) 45-50
13. Parhami F. Possible role of oxidized lipids in osteoporosis: could hyperlipidemia be a risk factor?. Prostaglandins Leukot Essent Fatty Acids 68 (2003) 373-378
14. Rajamannan N.M. Low-density lipoprotein and aortic stenosis. Heart 94 (2008) 1111-1112
15. Rajamannan N.M., Subramaniam M., and Rickard D. Human aortic valve calcification is associated with osteoblast phenotype. Circulation 107 (2003) 2181-2184
16. Banks L.M., Lees B., MacSweeney J.E., and Stevenson J.C. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease?. Eur. J. Clin. Invest. 24 (1994) 813-817
17. Tanko L.B., Bagger Y.Z., and Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif. Tissue Int. 73 (2003) 15-20
18. Broulik P.D., and Kapitola J. Interrelations between body weight, cigarette smoking and spine mineral density in osteoporotic Czech women. Endocr. Regul. 27 (1993) 57-60
19. Jie K.G., Bots M.L., Vermeer C., Witteman J.C., and Grobbee D.E. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif. Tissue Int. 59 (1996) 352-356
20. Laroche M., Pouilles J.M., Ribot C., Bendayan P., Bernard J., Boccalon H., and Mazieres B. Comparison of the bone mineral content of the lower limbs in men with ischaemic atherosclerotic disease. Clin. Rheumatol. 13 (1994) 611-614
21. Ouchi Y., Akishita M., de Souza A.C., Nakamura T., and Orimo H. Age-related loss of bone mass and aortic/aortic valve calcification-reevaluation of recommended dietary allowance of calcium in the elderly. Ann. N.Y. Acad. Sci. 676 (1993) 297-307
22. Tintut Y., Morony S., and Demer L.L. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb. Vasc. Biol. 24 (2004) e6-10
23. Barengolts E.I., Berman M., Kukreja S.C., Kouznetsova T., Lin C., and Chomka E.V. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif. Tissue Int. 62 (1998) 209-213
24. Browner W.S., Seeley D.G., Vogt T.M., and Cummings S.R. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 338 (1991) 355-358
25. Uyama O., Yoshimoto Y., Yamamoto Y., and Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 28 (1997) 1730-1732
26. Edwards C.J., Hart D.J., and Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355 (2000) 2218-2219
27. Callister T.Q., Raggi P., Cooil B., Lippolis N.J., and Russo D.J. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N. Engl. J. Med. 339 (1998) 1972-1978
28. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. Statins and fracture risk. JAMA 286 (2001) 669-670
29. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 (2000) 3205-3210
30. Schlienger R.G., Kraenzlin M.E., Jick S.S., and Meier C.R. Use of beta-blockers and risk of fractures. JAMA 292 (2004) 1326-1332
31. Parhami F., Morrow A.D., Balucan J., Leitinger N., Watson A.D., Tintut Y., Berliner J.A., and Demer L.L. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 680-687
32. Tintut Y., Parhami F., Tsingotjidou A., Tetradis S., Territo M., and Demer L.L. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J. Biol. Chem. 277 (2002) 14221-14226
33. Bustamante M., Diaz F., Munoz M., Gross H.J., Rivas C.I., Llancaqueo A., Nunez L., Campos L., Kirsten L., Grandon J., Gonzalez M., Barra V., Vera J.C., and Bachem M.G. Oxidized low density lipoproteins induce apoptosis in human lymphocytes: involvement of mitogen-activated protein kinases. Cell Mol. Biol. (Noisy-le-grand) 53 Suppl (2007) OL954-64
34. Caspar-Bauguil S., Tkaczuk J., Haure M.J., Durand M., Alcouffe J., Thomsen M., Salvayre R., and Benoist H. Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes. Biochem. J. 337 Pt 2 (1999) 269-274
35. Shamshiev A.T., Ampenberger F., Ernst B., Rohrer L., Marsland B.J., and Kopf M. Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J. Exp. Med. 204 (2007) 441-452
36. Trueta J., and Buhr A.J. The vascular contribution to osteogenesis. V. The vasculature supplying the epiphysial cartilage in rachitic rats. J. Bone Joint Surg. Br. 45 (1963) 572-581
37. Havel R., Eder H., and Bradgon J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34 (1955) 1345-1353
38. Vermes I., Haanen C., Steffens-Nakken H., and Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184 (1995) 39-51
39. Paigen B., Mitchell D., Reue K., Morrow A., Lusis A.J., and LeBoeuf R.C. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3763-3767
40. Paigen B., Morrow A., Brandon C., Mitchell D., and Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57 (1985) 65-73
41. Parhami F., Tintut Y., Beamer W.G., Gharavi N., Goodman W., and Demer L.L. Atherogenic high-fat diet reduces bone mineralization in mice. J. Bone Miner. Res. 16 (2001) 182-188
42. Huang M.S., Lu J., Ivanov Y., Sage A.P., Tseng W., Demer L.L., and Tintut Y. Hyperlipidemia impairs osteoanabolic effects of PTH. J. Bone Miner. Res. 23 (2008) 1672-1679
43. Kitchen C.M. Nonparametric vs parametric tests of location in biomedical research. Am. J. Ophthalmol. 147 (2009) 571-572
44. Theill L.E., Boyle W.J., and Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20 (2002) 795-823
45. Morrow J.D., and Roberts II L.J. The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol. 51 (1996) 1-9
46. Bochkov V.N., Mechtcheriakova D., Lucerna M., Huber J., Malli R., Graier W.F., Hofer E., Binder B.R., and Leitinger N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 99 (2002) 199-206
47. Huber J., Bochkov V.N., Binder B.R., and Leitinger N. The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. Antioxid. Redox Signal. 5 (2003) 163-169
48. Seyerl M., Bluml S., Kirchberger S., Bochkov V.N., Oskolkova O., Majdic O., and Stockl J. Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur. J. Immunol. 38 (2008) 778-787
49. Foncea R., Carvajal C., Almarza C., and Leighton F. Endothelial cell oxidative stress and signal transduction. Biol. Res. 33 (2000) 89-96
50. Bluml S., Kirchberger S., Bochkov V.N., Kronke G., Stuhlmeier K., Majdic O., Zlabinger G.J., Knapp W., Binder B.R., Stockl J., and Leitinger N. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J. Immunol. 175 (2005) 501-508
51. Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y., Tanaka T., Miwa S., Katsura Y., Kita T., and Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature 386 (1997) 73-77
52. Ohmori R., Momiyama Y., Nagano M., Taniguchi H., Egashira T., Yonemura A., Nakamura H., Kondo K., and Ohsuzu F. An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease. Clin. Cardiol. 27 (2004) 641-644
53. Tatsuguchi M., Furutani M., Hinagata J., Tanaka T., Furutani Y., Imamura S., Kawana M., Masaki T., Kasanuki H., Sawamura T., and Matsuoka R. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem. Biophys. Res. Commun. 303 (2003) 247-250
54. Moriwaki H., Kume N., Kataoka H., Murase T., Nishi E., Sawamura T., Masaki T., and Kita T. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Lett. 440 (1998) 29-32
55. Hara Y., Kusumi Y., Mitsumata M., Li X.K., and Fujino M. Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat. J. Thromb. Thrombolysis (2007)
56. Hansson G.K., Libby P., Schonbeck U., and Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91 (2002) 281-291
57. Parhami F., Jackson S., Tintut Y., Le V., Balucan J., Territo M., and Demer L. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J. Bone Miner. Res. 14 (1999) 2067-2078
58. von der Recke P., Hansen M.A., and Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am. J. Med. 106 (1999) 273-278
59. Towler D.A. The osteogenic-angiogenic interface: novel insights into the biology of bone formation and fracture repair. Curr. Osteoporos. Rep. 6 (2008) 67-71
60. Bensinger S.J., Bradley M.N., Joseph S.B., Zelcer N., Janssen E.M., Hausner M.A., Shih R., Parks J.S., Edwards P.A., Jamieson B.D., and Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134 (2008) 97-111
61. Boullier A., Li Y., Quehenberger O., Palinski W., Tabas I., Witztum J.L., and Miller Y.I. Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1169-1176
62. Kuge Y., Kume N., Ishino S., Takai N., Ogawa Y., Mukai T., Minami M., Shiomi M., and Saji H. Prominent lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1) expression in atherosclerotic lesions is associated with tissue factor expression and apoptosis in hypercholesterolemic rabbits. Biol. Pharm. Bull 31 (2008) 1475-1482
63. Satoh H., Kiyota E., Terasaki Y., Sawamura T., Takagi K., Mizuta H., and Takeya M. Expression and localization of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in murine and human placentas. J. Histochem. Cytochem. 56 (2008) 773-784
64. Simopoulou T., Malizos K.N., and Tsezou A. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human articular chondrocytes. Clin. Exp. Rheumatol. 25 (2007) 605-612
65. Liang M., Zhang P., and Fu J. Up-regulation of LOX-1 expression by TNF-alpha promotes trans-endothelial migration of MDA-MB-231 breast cancer cells. Cancer Lett. 258 (2007) 31-37
66. Chen X.P., Zhang T.T., and Du G.H. Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis?. Cardiovasc. Drug Rev. 25 (2007) 146-161
67. Blake G.J., Rifai N., Buring J.E., and Ridker P.M. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 108 (2003) 2993-2999
68. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
69. Kita T., Kume N., Minami M., Hayashida K., Murayama T., Sano H., Moriwaki H., Kataoka H., Nishi E., Horiuchi H., Arai H., and Yokode M. Role of oxidized LDL in atherosclerosis. Ann. N.Y. Acad. Sci. 947 (2001) 199-205 discussion 205-6
70. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272 (1997) 20963-20966
71. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., and Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84 (1989) 1086-1095
72. Young I.S., and McEneny J. Lipoprotein oxidation and atherosclerosis. Biochem. Soc. Trans. 29 (2001) 358-362
73. Zhou X., Robertson A.K., Hjerpe C., and Hansson G.K. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 864-870
74. Wu R., Giscombe R., Holm G., and Lefvert A.K. Induction of human cytotoxic T lymphocytes by oxidized low density lipoproteins. Scand. J. Immunol. 43 (1996) 381-384
75. Cruz D., Watson A.D., Miller C.S., Montoya D., Ochoa M.T., Sieling P.A., Gutierrez M.A., Navab M., Reddy S.T., Witztum J.L., Fogelman A.M., Rea T.H., Eisenberg D., Berliner J., and Modlin R.L. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J. Clin. Invest. 118 (2008) 2917-2928
76. Chen W., Gardner J.P., Kimura M., Brimacombe M., Cao X., Srinivasan S.R., Berenson G.S., and Aviv A. Leukocyte telomere length is associated with HDL cholesterol levels: the Bogalusa heart study. Atherosclerosis (2009)
77. Tsirpanlis G., Chatzipanagiotou S., Boufidou F., Kordinas V., Zoga M., Alevyzaki F., Stamatelou K., Frangou E., Savva L., and Nicolaou C. Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients. Nephrology (Carlton) 11 (2006) 506-509
78. Delpierre C., Bonnet E., Marion-Latard F., Aquilina C., Obadia M., Marchou B., Massip P., Perret B., and Bernard J. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. J. Clin. Densitom. 10 (2007) 376-380